The PCSK9i revolution: important changes to PBS eligibility
These next-generation lipid therapies may see more patients benefit, say experts
These next-generation lipid therapies may see more patients benefit, say experts
The underlying mechanisms include medication, researchers say
Dr Ralph Audehm says resourcing primary care is vital to address the gaps in care across the nation revealed in new 'heart maps'.
abstract: More evidence for PCSK9 inhibitors in secondary prevention, says cardiologist
The study is unusual in covering a a wide range of symptoms, researchers say.
But results of the VERTIS CV trial confirm that ertugliflozin cuts admissions for heart failure.
Video highlights from the ADA conferenceÂ
Worldwide, people in urban areas appear to be most at risk, results show.
Study highlights importance of considering impact of comorbid hypertension and depression on CV outcomes.
But findings are less applicable as patients age, says Australian expert.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.